S D Patterson

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins
    S D Patterson
    Amgen Inc, Thousand Oaks, CA, USA
    Electrophoresis 17:877-91. 1996
  2. ncbi The role of biomarkers in the future of drug development
    Scott D Patterson
    Department of Molecular Sciences, Amgen, Inc, 1 Amgen Center Drive, MS 38 3 A Thousand Oaks, CA 91320, USA
    Expert Opin Drug Discov 1:199-204. 2006
  3. ncbi A comparability study of 5 commercial KRAS tests
    Kelly Oliner
    Department of Molecular Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Diagn Pathol 5:23. 2010
  4. ncbi Proteomics: the industrialization of protein chemistry
    S D Patterson
    Amgen Inc, Biochemistry, Thousand Oaks, California 91320 1789, USA
    Curr Opin Biotechnol 11:413-8. 2000
  5. ncbi Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat--a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation
    Scott D Patterson
    Medical Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Proteomics Clin Appl 4:883-7. 2010
  6. ncbi Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
    Scott D Patterson
    Medical Sciences, Amgen Inc, 1 Amgen Center Drive MS 38 3 A, Thousand Oaks, CA 91320, USA
    Pharmacogenomics 12:939-51. 2011
  7. ncbi Mutation of Cys672 allows recombinant expression of activatible macrophage-stimulating protein
    R C Wahl
    Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    J Biol Chem 272:15053-6. 1997
  8. ncbi Automated LC-LC-MS-MS platform using binary ion-exchange and gradient reversed-phase chromatography for improved proteomic analyses
    M T Davis
    Department of Biochemistry, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Chromatogr B Biomed Sci Appl 752:281-91. 2001
  9. ncbi Protein identification and characterization by mass spectrometry
    S D Patterson
    Amgen, Inc, Thousand Oaks, California, USA
    Curr Protoc Mol Biol . 2001
  10. ncbi The value of banked samples for oncology drug discovery and development
    Peter M Shaw
    Department of Genetics, Early Translational Sciences, Merck Research Laboratories, West Point, PA, USA
    J Natl Cancer Inst Monogr 2011:46-9. 2011

Collaborators

Detail Information

Publications10

  1. ncbi Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins
    S D Patterson
    Amgen Inc, Thousand Oaks, CA, USA
    Electrophoresis 17:877-91. 1996
    ..In one case the identified protein clearly did not correspond to the radiolabeled band, but to a protein contaminant from the column. The advantages and pitfalls of the approach are discussed...
  2. ncbi The role of biomarkers in the future of drug development
    Scott D Patterson
    Department of Molecular Sciences, Amgen, Inc, 1 Amgen Center Drive, MS 38 3 A Thousand Oaks, CA 91320, USA
    Expert Opin Drug Discov 1:199-204. 2006
    ..The strategy to achieve these aims and how this can lead to information that can be fed back into drug discovery is described in this perspective...
  3. ncbi A comparability study of 5 commercial KRAS tests
    Kelly Oliner
    Department of Molecular Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Diagn Pathol 5:23. 2010
    ..Therefore, an accurate and readily available analysis of KRAS mutational status is needed. The aim of this study was to evaluate concordance between KRAS assays performed by 6 different laboratories...
  4. ncbi Proteomics: the industrialization of protein chemistry
    S D Patterson
    Amgen Inc, Biochemistry, Thousand Oaks, California 91320 1789, USA
    Curr Opin Biotechnol 11:413-8. 2000
    ....
  5. ncbi Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat--a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation
    Scott D Patterson
    Medical Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Proteomics Clin Appl 4:883-7. 2010
    ..Although not meant to be all encompassing, important elements for proteomics researchers to consider are presented...
  6. ncbi Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
    Scott D Patterson
    Medical Sciences, Amgen Inc, 1 Amgen Center Drive MS 38 3 A, Thousand Oaks, CA 91320, USA
    Pharmacogenomics 12:939-51. 2011
    ..The primary utility of the PRA is to define a process that provides robust scientific evidence for decision-making in situations where it is not necessary, nor practical or ethical to conduct a new prospective clinical study...
  7. ncbi Mutation of Cys672 allows recombinant expression of activatible macrophage-stimulating protein
    R C Wahl
    Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    J Biol Chem 272:15053-6. 1997
    ....
  8. ncbi Automated LC-LC-MS-MS platform using binary ion-exchange and gradient reversed-phase chromatography for improved proteomic analyses
    M T Davis
    Department of Biochemistry, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Chromatogr B Biomed Sci Appl 752:281-91. 2001
    ..In comparative analyses of a highly complex peptide digest mixture a >40% increase in the number of peptide and protein identifications was achieved using this multidimensional platform compared to an unfractionated control...
  9. ncbi Protein identification and characterization by mass spectrometry
    S D Patterson
    Amgen, Inc, Thousand Oaks, California, USA
    Curr Protoc Mol Biol . 2001
    ..The mass spectrometric methods referred to in this overview include matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and electrospray ionization mass spectrometry (ESI-MS)...
  10. ncbi The value of banked samples for oncology drug discovery and development
    Peter M Shaw
    Department of Genetics, Early Translational Sciences, Merck Research Laboratories, West Point, PA, USA
    J Natl Cancer Inst Monogr 2011:46-9. 2011
    ....